July 30, 2021
“…The company posted better-than-expected earnings results on Tuesday, but Wall Street appears more excited about the industrial conglomerate’s improving cash flow. In addition to beating estimates, GE (ticker: GE) raised its full-year free-cash-flow guidance for its industrial operations to a midpoint of… Continue Reading…
July 21, 2021
“Oil is likely to jump to $80 a barrel by year end amid expanding demand and a lack of supply, according to JP Morgan analysts led by Joyce Chang. The upcycle in energy prices is supported by a surge in demand as the world… Continue Reading…
July 9, 2021
“Aerpio Pharmaceuticals (ARPO) is a biopharmaceutical company focused on developing compounds that activate Tie2. Tie2 is considered a key regulator of vascular stability, and ARPO “believes that activation of Tie2 may have therapeutic potential” for different indications. In Q1, ARPO… Continue Reading…
June 22, 2021
“Paymentus Holdings (PAY)… Overall, PAY has received 8 recent analyst reviews, breaking down to 6 Buys versus 2 Holds and making the analyst consensus rating a Strong Buy. The stock has current trading price of $32.35 and an average price… Continue Reading…
June 21, 2021
“Oil could hit $100 per barrel next year as demand outstrips supply, according to Bank of America. The firm identified three factors on both the demand and supply side that should support prices into 2022. Analysts led by Francisco Blanch… Continue Reading…
February 24, 2021
“Annaly Capital Management (NLY)… Overall, there is broad agreement on Wall Street about NLY’s quality, as shown by the 7 to 1 split among the analyst reviews, favoring Buy over Hold and giving the stock a Strong Buy analyst consensus… Continue Reading…
February 9, 2021
“Ares Commercial Real Estate (ACRE)… Only one other analyst has posted a recent ACRE review, also rating the stock a Buy, which makes the analyst consensus here a Moderate Buy. Shares are priced at $12.28, and their $12.75 average price target… Continue Reading…
December 31, 2020
“New Residential Investment (NRZ)… It’s not often that the analysts all agree on a stock, so when it does happen, take note. NRZ’s Strong Buy consensus rating is based on a unanimous 8 Buys. The stock’s $11.36 average price target… Continue Reading…
December 2, 2020
“Cellectar Biosciences (CLRB)… Are other analysts in agreement? They are. 5 Buys and no Holds or Sells have been issued in the last three months. So, the message is clear: CLRB is a Strong Buy. Given the $5.48 average price… Continue Reading…
Recent Comments